Epidemics

Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in  DR Congo with 48% Crude Fatality Rate, Says NanoViricides

Staff September 15, 2026

SHELTON, CT / ACCESS Newswire / September 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo

Staff September 8, 2026

SHELTON, CT / ACCESS Newswire / September 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

Staff August 18, 2026

SHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

Staff August 10, 2026

SHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

Viemed Healthcare Announces Second Quarter 2026 Financial Results

Staff August 3, 2026

LAFAYETTE, LA / ACCESS Newswire / August 3, 2026 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national...

CLINUVEL implements strategic reorganisation to refocus on U.S. markets

Staff July 23, 2026

MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today...

CLINUVEL’s ADS to commence trading on Nasdaq

Staff July 20, 2026

CUVL to trade on the highest tier – Global Select MarketMELBOURNE, Australia and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE)...

Vireo Growth Inc. Completes Acquisition of Pennsylvania Dispensary License Transaction

Staff July 18, 2026

MINNEAPOLIS, July 17, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), today announced...

Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants

Staff July 10, 2026

Daix (France), New York City (New York, United States), July 9, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva”...

Research Analyst Report on NanoViricides Rates Company “Outperform”; Separately, A “Fireside Chat” Interview of the Company’s President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily

Staff July 8, 2026

SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

Enhanced Group Announces $50 Million Strategic Financing Led by Enhanced Co-Founder and Chairman Christian Angermayer; Management Expects Company Fully Funded Through Profitability

Staff June 15, 2026

Financing Led by Christian Angermayer's Family Office Apeiron Investment Group with Participation from Co-Founder and CEO Maximilian Martin and Leading...

Vireo Growth Inc. Completes Acquisition of Bridgewell Agribusiness LLC and Plans to Acquire Dispensaries in Nevada and Maryland

Staff June 6, 2026

MINNEAPOLIS, June 05, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), today announced...

Trust & Will Launches Nonprofit Featureship Program, Giving Mission-Driven Organizations a Scalable Way to Reach Donors at the Moment They Are Planning Their Legacy

Staff June 4, 2026

St. Jude Children's Research Hospital, Doctors Without Borders, and Susan G. Komen Join as Featured Organizations of the New Program SAN...

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

Staff June 4, 2026

Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needsTARRYTOWN,...

RadNet Announces a Proposed $200 Million Incremental Term Loan to Fund Strategic Growth Opportunities

Staff June 3, 2026

LOS ANGELES, June 03, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective, fixed-site...

Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout

Staff June 2, 2026

Secured a new debt financing with funds and accounts managed by BlackRock and Claret Capital Partners, respectively for up to...

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

Staff May 31, 2026

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a...

Vireo Growth Inc. to Acquire Bridgewell Agribusiness LLC

Staff May 25, 2026

MINNEAPOLIS, May 25, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), today announced...

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

Staff May 16, 2026

The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement...

Vireo Growth Inc. Announces First Quarter 2026 Results

Staff May 12, 2026

Q1 GAAP revenue of $106.2 million increased 333.5% year-over-year, driven by recently closed M&A transactions Moves to 4th largest cannabis...